MX2020003863A - Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. - Google Patents
Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.Info
- Publication number
- MX2020003863A MX2020003863A MX2020003863A MX2020003863A MX2020003863A MX 2020003863 A MX2020003863 A MX 2020003863A MX 2020003863 A MX2020003863 A MX 2020003863A MX 2020003863 A MX2020003863 A MX 2020003863A MX 2020003863 A MX2020003863 A MX 2020003863A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- sup
- treatment
- sub
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 102000013462 Interleukin-12 Human genes 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 102000013264 Interleukin-23 Human genes 0.000 abstract 1
- 108010065637 Interleukin-23 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000007306 turnover Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención describe compuestos de acuerdo con la Fórmula I: en donde R1, L1, R2, L2, R3, Cy, y el subíndice n son como se define en el presente documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que comprenden los mismos y métodos de tratamiento que los usan, para la profilaxis y/o el tratamiento de enfermedades alérgicas, enfermedades inflamatorias, enfermedades metabólicas, enfermedades autoinflamatorias, enfermedades autoinmunes, enfermedades proliferativas, rechazo de trasplantes, enfermedades que implican el deterioro del recambio de cartílago, malformaciones congénitas del cartílago y/o enfermedades asociadas con la hipersecreción de IFNa, IL12 y/o IL23 mediante la administración del compuesto de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717260.2A GB201717260D0 (en) | 2017-10-20 | 2017-10-20 | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2018/077677 WO2019076716A1 (en) | 2017-10-20 | 2018-10-11 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003863A true MX2020003863A (es) | 2020-08-13 |
Family
ID=60481889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003863A MX2020003863A (es) | 2017-10-20 | 2018-10-11 | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11564923B2 (es) |
| EP (2) | EP4265254A3 (es) |
| JP (2) | JP7292271B2 (es) |
| KR (1) | KR102757425B1 (es) |
| CN (2) | CN117534670A (es) |
| AR (1) | AR113784A1 (es) |
| AU (2) | AU2018350592B2 (es) |
| CA (1) | CA3079449A1 (es) |
| CO (1) | CO2020005200A2 (es) |
| DK (1) | DK3697784T5 (es) |
| ES (1) | ES2967432T3 (es) |
| FI (1) | FI3697784T5 (es) |
| GB (1) | GB201717260D0 (es) |
| HR (1) | HRP20231315T1 (es) |
| HU (1) | HUE063998T2 (es) |
| IL (2) | IL273943B2 (es) |
| LT (1) | LT3697784T (es) |
| MA (1) | MA50391B1 (es) |
| MX (1) | MX2020003863A (es) |
| MY (1) | MY205443A (es) |
| PH (1) | PH12020550230A1 (es) |
| PL (1) | PL3697784T3 (es) |
| PT (1) | PT3697784T (es) |
| RS (1) | RS64800B1 (es) |
| SG (1) | SG11202003516TA (es) |
| SI (1) | SI3697784T1 (es) |
| SM (1) | SMT202300377T1 (es) |
| TW (2) | TWI805629B (es) |
| WO (1) | WO2019076716A1 (es) |
| ZA (1) | ZA202002166B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| EP3976612A4 (en) * | 2019-05-28 | 2023-04-26 | Mankind Pharma Ltd | NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 |
| JP2023503343A (ja) | 2019-11-26 | 2023-01-27 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | イオンチャネルモジュレーター |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| MX2024000517A (es) | 2021-07-12 | 2024-01-31 | Galapagos Nv | Tratamiento de enfermedades inflamatorias. |
| TW202339749A (zh) | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| WO2023161327A1 (en) * | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
| WO2023161326A1 (en) | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
| JP7882100B2 (ja) * | 2022-12-07 | 2026-06-30 | 富士通株式会社 | 情報処理プログラム、情報処理方法および情報処理装置 |
| EP4652166A1 (en) | 2023-01-18 | 2025-11-26 | Galapagos N.V. | Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders |
| CN120584114A (zh) | 2023-01-19 | 2025-09-02 | 加拉帕戈斯股份有限公司 | 用于治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病和增生性疾病的咪唑并[4,5-b]吡啶衍生物 |
| WO2026098666A1 (zh) * | 2024-11-11 | 2026-05-15 | 杭州领业医药科技有限公司 | 一种tyk2抑制剂的共晶及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| ES2567552T3 (es) | 2012-01-30 | 2016-04-25 | Cephalon, Inc. | Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2017012647A1 (en) * | 2015-07-20 | 2017-01-26 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| AR105400A1 (es) | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
-
2017
- 2017-10-20 GB GBGB1717260.2A patent/GB201717260D0/en not_active Ceased
-
2018
- 2018-10-11 DK DK18788711.2T patent/DK3697784T5/da active
- 2018-10-11 RS RS20231045A patent/RS64800B1/sr unknown
- 2018-10-11 CN CN202311478101.5A patent/CN117534670A/zh active Pending
- 2018-10-11 MA MA50391A patent/MA50391B1/fr unknown
- 2018-10-11 SI SI201831002T patent/SI3697784T1/sl unknown
- 2018-10-11 EP EP23191626.3A patent/EP4265254A3/en active Pending
- 2018-10-11 SG SG11202003516TA patent/SG11202003516TA/en unknown
- 2018-10-11 JP JP2020521991A patent/JP7292271B2/ja active Active
- 2018-10-11 MY MYPI2020001882A patent/MY205443A/en unknown
- 2018-10-11 EP EP18788711.2A patent/EP3697784B9/en active Active
- 2018-10-11 US US16/757,189 patent/US11564923B2/en active Active
- 2018-10-11 ES ES18788711T patent/ES2967432T3/es active Active
- 2018-10-11 CA CA3079449A patent/CA3079449A1/en active Pending
- 2018-10-11 CN CN201880067863.7A patent/CN111225916B/zh active Active
- 2018-10-11 AU AU2018350592A patent/AU2018350592B2/en active Active
- 2018-10-11 IL IL273943A patent/IL273943B2/en unknown
- 2018-10-11 HR HRP20231315TT patent/HRP20231315T1/hr unknown
- 2018-10-11 SM SM20230377T patent/SMT202300377T1/it unknown
- 2018-10-11 MX MX2020003863A patent/MX2020003863A/es unknown
- 2018-10-11 PT PT187887112T patent/PT3697784T/pt unknown
- 2018-10-11 KR KR1020207014284A patent/KR102757425B1/ko active Active
- 2018-10-11 WO PCT/EP2018/077677 patent/WO2019076716A1/en not_active Ceased
- 2018-10-11 PL PL18788711.2T patent/PL3697784T3/pl unknown
- 2018-10-11 FI FIEP18788711.2T patent/FI3697784T5/fi active
- 2018-10-11 HU HUE18788711A patent/HUE063998T2/hu unknown
- 2018-10-11 IL IL302615A patent/IL302615B2/en unknown
- 2018-10-11 LT LTEPPCT/EP2018/077677T patent/LT3697784T/lt unknown
- 2018-10-19 TW TW107136998A patent/TWI805629B/zh active
- 2018-10-19 AR ARP180103068A patent/AR113784A1/es active IP Right Grant
- 2018-10-19 TW TW112121026A patent/TWI866258B/zh active
-
2020
- 2020-04-07 PH PH12020550230A patent/PH12020550230A1/en unknown
- 2020-04-27 CO CONC2020/0005200A patent/CO2020005200A2/es unknown
- 2020-05-04 ZA ZA2020/02166A patent/ZA202002166B/en unknown
-
2022
- 2022-12-27 US US18/146,698 patent/US12472181B2/en active Active
-
2023
- 2023-03-10 AU AU2023201522A patent/AU2023201522B2/en active Active
- 2023-06-06 JP JP2023093474A patent/JP7654031B2/ja active Active
-
2025
- 2025-10-21 US US19/364,059 patent/US20260183288A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2020013275A (es) | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. | |
| MY201849A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of disease | |
| MX2021013803A (es) | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12017501061A1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| MX355653B (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| PH12018501849A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| TW201613873A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| PH12021552376A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| PH12021552680A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| PH12021552032A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| NZ803938A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. | |
| MX2025008076A (es) | Derivados de imidazo[4,5-b] piridina utiles para el tratamiento de enfermedades alergicas, enfermedades inflamatorias, enfermedades metabolicas, enfermedades autoinflamatorias, enfermedades autoinmunes y enfermedades proliferativas |